Table 2.
Univariate Analysis for PFS of the 32 Patients with EOC According to Baseline Characteristics
| Characteristics | No. of Patients | Median PFS (Months) | 95% CI | P |
|---|---|---|---|---|
| Age (years) | ||||
| <56 | 15 | 6.8 | 3.55–10.05 | 0.548 |
| ≥56 | 17 | 6.1 | 2.54–9.66 | |
| ECOG PS score | ||||
| 0–1 | 18 | 8.5 | 5.16–12.84 | 0.027 |
| 2 | 14 | 5.5 | 2.31–8.69 | |
| FIGO stage | ||||
| III | 21 | 9.7 | 5.98–13.42 | 0.016 |
| IV | 11 | 5.5 | 2.11–8.89 | |
| Histology of EOC | ||||
| Serous | 23 | 7.6 | 4.13–11.07 | 0.378 |
| Mixed | 9 | 6.1 | 3.19–9.01 | |
| First-line platinum response | ||||
| Platinum refractory and platinum resistant | 22 | 5.5 | 2.34–8.66 | 0.046 |
| Platinum sensitive | 10 | 8.5 | 5.85–11.15 | |
| Tumor differentiation | ||||
| Well-differentiated and Intermediate differentiated | 16 | 7.6 | 4.35–10.85 | 0.102 |
| Poorly differentiated | 16 | 5.5 | 2.18–8.82 | |
| Lines of previous treatment regimens | ||||
| 2 | 5 | 7.6 | 5.08–10.12 | 0.418 |
| ≥3 | 27 | 6.1 | 3.67–8.53 | |
| Previous targeted drugs therapy | ||||
| Yes | 12 | 7.6 | 4.97–10.23 | 0.618 |
| No | 20 | 6.8 | 3.73–9.87 | |
| Initial dosage of anlotinib (mg) | ||||
| 12 | 26 | 6.8 | 2.83–10.77 | 0.336 |
| 10 | 6 | 6.1 | 3.02–9.18 | |
| PD-1 blockades | ||||
| Camrelizumab | 18 | 6.1 | 3.46–8.74 | 0.572 |
| Sintilimab | 9 | 6.8 | 3.78–9.82 | |
| Pembrolizumab | 5 | 7.6 | 4.16–11.04 |
Abbreviations: PFS, progression-free survival; EOC, epithelial ovarian cancer; ECOG, Eastern Cooperative Oncology Group; PS, performance status; FIGO, Federation of Gynecology Obstetrics; PD-1, programmed cell death protein 1; CI, confidence interval.